Corrigendum: Safety of Semaglutide

Saved in:
Bibliographic Details
Published inFrontiers in endocrinology (Lausanne) Vol. 12; p. 786732
Main Authors Smits, Mark M., Van Raalte, Daniël H.
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 10.11.2021
Subjects
Endocrinology
glucagon-like peptide-1 receptor agonist (GLP-1RA)
oral
safety
semaglutide
subcutaneous
type 2 diabetes
Online AccessGet full text

Cover

More Information
Bibliography:corrigendum
SourceType-Other Sources-1
content type line 63
ObjectType-Correction/Retraction-1
Edited by: Francesco Giorgino, University of Bari Aldo Moro, Italy
This article was submitted to Clinical Diabetes, a section of the journal Frontiers in Endocrinology
Reviewed by: Stephen Bain, Swansea University, United Kingdom
ISSN:1664-2392
1664-2392
DOI:10.3389/fendo.2021.786732